Neuroprotective effects of brilliant blue G on the brain following traumatic brain injury in rats

Wang,Yong‑Chao; Cui,Ying; Cui,Jian‑Zhong; Sun,Li‑Qian; Cui,Chang‑Meng; Zhang,Hong‑Ao; Zhu,Hui‑Xing; Li,Ran; Tian,Yan‑Xia; Gao,Jun‑Ling

doi:10.3892/mmr.2015.3607

Neuroprotective effects of brilliant blue G on the brain following traumatic brain injury in rats

Authors:
- Yong‑Chao Wang
- Ying Cui
- Jian‑Zhong Cui
- Li‑Qian Sun
- Chang‑Meng Cui
- Hong‑Ao Zhang
- Hui‑Xing Zhu
- Ran Li
- Yan‑Xia Tian
- Jun‑Ling Gao
View Affiliations

Affiliations: Department of Basic Medical Science, Hebei United University, Tangshan, Hebei 063000, P.R. China, Department of Surgery, Tangshan Workers' Hospital, Tangshan, Hebei 063000, P.R. China, Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
Published online on: April 14, 2015 https://doi.org/10.3892/mmr.2015.3607
Pages: 2149-2154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The P2X7 inhibitor, brilliant blue G (BBG), has been reported as a neuroprotective drug against a variety of disorders, including neuropathic pain and brain ischemia. Currently, no studies have examined the potential for BBG to provide neuroprotection in animal models of TBI. The aim of the present study was to investigate the neuroprotective effect of BBG on TBI and to determine the underlying mechanisms. The rats were subjected to a diffuse cortical impact injury caused by a modified weight‑drop device, and then divided randomly into three groups: the sham‑operated, BBG treatment and vehicle groups. In the BBG treatment group, 50 mg/kg brilliant blue G (BBG; 100% pure), a highly specific and clinically useful P2X7 antagonist, was administered via the tail vein 15 min prior to or up to 8 h following TBI. The co‑localization of NeuN and protein kinase Cγ (PKCγ) was followed with immunofluorescent staining. The expression of P2X7, PKCγ and inflammatory cytokines was identified by western blot analysis. Wet‑dry weight method was used to evaluate brain edema, and motor function outcome was examined using the neurological severity score. The present study demonstrated that the administration of BBG attenuated TBI‑induced cerebral edema and the associated motor deficits. Following trauma, BBG treatment significantly reduced the levels of PKCγ and interleukin‑1β in the cortex. The results provide in vivo evidence that BBG exerted neuroprotective effects by attenuating brain edema and improving neurological functions via reducing PKCγ and interleukin-1β levels following TBI.

View Figures

View References

1	Nortje J and Menon DK: Traumatic brain injury: physiology, mechanisms, and outcome. Curr Opin Neurol. 17:711–718. 2004. View Article : Google Scholar : PubMed/NCBI
2	Bramlett HM and Dietrich WD: Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res. 161:125–141. 2007.PubMed/NCBI
3	Song SX, Gao JL, Wang KJ, et al: Attenuation of brain edema and spatial learning deficits by the inhibition of NADPH oxidase activity using apocynin following diffuse traumatic brain injury in rats. Mol Med Rep. 7:327–331. 2013.
4	Levin HS, Eisenberg HM, Gary HE, et al: Intracranial hypertension in relation to memory functioning during the first year after severe head injury. Neurosurgery. 28:196–199. 1991. View Article : Google Scholar : PubMed/NCBI
5	Saul TG and Ducker TB: Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J Neurosurg. 56:498–503. 1982. View Article : Google Scholar : PubMed/NCBI
6	Chessell IP, Hatcher JP, Bountra C, et al: Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 114:386–396. 2005. View Article : Google Scholar : PubMed/NCBI
7	Labasi JM, Petrushova N, Donovan C, et al: Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol. 168:6436–6445. 2002. View Article : Google Scholar : PubMed/NCBI
8	Le Feuvre R, Brough D and Rothwell N: Extracellular ATP and P2X7 receptors in neurodegeneration. Eur J Pharmacol. 447:261–269. 2002. View Article : Google Scholar : PubMed/NCBI
9	Solle M, Labasi J, Perregaux DG, et al: Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem. 276:125–132. 2001. View Article : Google Scholar
10	Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B and Posmantur R: P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer’s disease. J Biol Chem. 278:13309–13317. 2003. View Article : Google Scholar : PubMed/NCBI
11	Sperlágh B, Vizi ES, Wirkner K and Illes P: P2X7 receptors in the nervous system. Prog Neurobiol. 78:327–346. 2006. View Article : Google Scholar : PubMed/NCBI
12	Sanz JM and Di Virgilio F: Kinetics and mechanism of ATP-dependent IL-1beta release from microglial cells. J Immunol. 164:4893–4898. 2000. View Article : Google Scholar : PubMed/NCBI
13	Surprenant A, Rassendren F, Kawashima E, North R and Buell G: The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 272:735–738. 1996. View Article : Google Scholar : PubMed/NCBI
14	Calogero S, Grassi F, Aguzzi A, et al: The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet. 22:276–280. 1999. View Article : Google Scholar : PubMed/NCBI
15	Takenouchi T, Sugama S, Iwamaru Y, Hashimoto M and Kitani H: Modulation of the ATP-lnduced release and processing of IL-1beta in microglial cells. Crit Rev Immunol. 29:335–345. 2009. View Article : Google Scholar : PubMed/NCBI
16	Folkersma H, Brevé JJ, Tilders FJ, Cherian L, Robertson CS and Vandertop WP: Cerebral microdialysis of interleukin (IL)-1beta and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats. Acta Neurochir (Wien). 150:1277–1284. 2008. View Article : Google Scholar
17	Herx LM, Rivest S and Yong VW: Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1β is required for the production of ciliary neurotrophic factor. J Immunol. 165:2232–2239. 2000. View Article : Google Scholar : PubMed/NCBI
18	Kamm K, Vanderkolk W, Lawrence C, Jonker M and Davis AT: The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma Acute Care Surg. 60:152–157. 2006. View Article : Google Scholar
19	Kinoshita K, Chatzipanteli K, Vitarbo E, Truettner JS, Alonso OF and Dietrich WD: Interleukin-1beta messenger ribonucleic acid and protein levels after fluid-percussion brain injury in Rats: importance of injury severity and brain temperature. Neurosurgery. 51:195–203. 2002. View Article : Google Scholar : PubMed/NCBI
20	Laird MD, Sukumari-Ramesh S, Swift AE, Meiler SE, Vender JR and Dhandapani KM: Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4? J Neurochem. 113:637–648. 2010. View Article : Google Scholar : PubMed/NCBI
21	Taupin V, Toulmond S, Serrano A, Benavides J and Zavala F: Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion: Influence of pre-and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol. 42:177–185. 1993. View Article : Google Scholar : PubMed/NCBI
22	Shiozaki T, Hayakata T, Tasaki O, et al: Cerebrospinal fluid concentrations of anti-inflammatory mediators in earlyphase severe traumatic brain injury. Shock. 23:406–410. 2005. View Article : Google Scholar : PubMed/NCBI
23	Hayakata T, Shiozaki T, Tasaki O, et al: Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock. 22:102–107. 2004. View Article : Google Scholar : PubMed/NCBI
24	Chiaretti A, Genovese O, Aloe L, et al: Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst. 21:185–193. 2005. View Article : Google Scholar
25	Clausen F, Hånell A, Björk M, et al: Neutralization of interleukin-1beta modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice. Eur J Neurosci. 30:385–396. 2009. View Article : Google Scholar : PubMed/NCBI
26	Jones NC, Prior MJ, Burden Teh E, Marsden CA, Morris PG and Murphy S: Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. Eur J Neurosci. 22:72–78. 2005. View Article : Google Scholar : PubMed/NCBI
27	Tehranian R, Andell-Jonsson S, Beni SM, et al: Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma. 19:939–951. 2002. View Article : Google Scholar : PubMed/NCBI
28	Toulmond S and Rothwell NJ: Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res. 671:261–266. 1995. View Article : Google Scholar : PubMed/NCBI
29	Kishimoto A, Mikawa K, Hashimoto K, et al: Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J Biol Chem. 264:4088–4092. 1989.PubMed/NCBI
30	Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9:484–496. 1995.PubMed/NCBI
31	Ohno S: The distinct biological potential of PKC isotypes. Protein Kinase C. Parker PJ and Deckker LV: RG Landes; Texas, USA: pp. 178–188. 1997
32	Saito N, Kikkawa U, Nishizuka Y and Tanaka C: Distribution of protein kinase C-like immunoreactive neurons in rat brain. J Neurosci. 8:369–382. 1988.PubMed/NCBI
33	Huang FL, Yoshida Y, Nakabayashi H, Young WS III and Huang KP: Immunocytochemical localization of protein kinase C isozymes in rat brain. J Neurosci. 8:4734–4744. 1988.PubMed/NCBI
34	Tanaka C and Saito N: Localization of subspecies of protein kinase C in the mammalian central nervous system. Neurochem Int. 21:499–512. 1992. View Article : Google Scholar : PubMed/NCBI
35	Matsumoto S, Murozono M, Nagaoka D, et al: Isoflurane inhibits protein kinase Cgamma and calcium/calmodulin dependent protein kinase II-alpha translocation to synaptic membranes in ischemic mice brains. Neurochem Res. 33:2302–2309. 2008. View Article : Google Scholar : PubMed/NCBI
36	Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H and Demetriadou K: A new model of diffuse brain injury in rats: Part I: Pathophysiology and biomechanics. J Neurosurg. 80:291–300. 1994. View Article : Google Scholar : PubMed/NCBI
37	Tang J, Liu J, Zhou C, et al: Mmp-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cerebral Blood Flow Metab. 24:1133–1145. 2004. View Article : Google Scholar
38	Beni-Adani L, Gozes I, Cohen Y, et al: A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther. 296:57–63. 2001.
39	Whelan-Goodinson R, Ponsford J, Johnston L and Grant F: Psychiatric disorders following traumatic brain injury: their nature and frequency. J Head Trauma Rehabil. 24:324–332. 2009. View Article : Google Scholar : PubMed/NCBI
40	Rogers JM and Read CA: Psychiatric comorbidity following traumatic brain injury. Brain Inj. 21:1321–1333. 2007. View Article : Google Scholar : PubMed/NCBI
41	Wang X, Arcuino G, Takano T, et al: P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med. 10:821–827. 2004. View Article : Google Scholar : PubMed/NCBI
42	Kimbler DE, Shields J, Yanasak N, Vender JR and Dhandapani KM: Activation of P2X7 promotes cerebral edema and neurological injury after traumatic brain injury in mice. PloS One. 7:e412292012. View Article : Google Scholar : PubMed/NCBI
43	Elssner A, Duncan M, Gavrilin M and Wewers MD: A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1beta processing and release. J Immunol. 172:4987–4994. 2004. View Article : Google Scholar : PubMed/NCBI
44	Peng W, Cotrina ML, Han X, et al: Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proce Natl Acad Sci USA. 106:12489–12493. 2009. View Article : Google Scholar
45	Iwashita A, Muramatsu Y, Yamazaki T, et al: Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther. 320:1087–1096. 2007. View Article : Google Scholar
46	Karpiak SE, Mahadik SP and Wakade CG: Ganglioside reduction of ischemic injury. Crit Rev Neurobiol. 5:221–237. 1990.PubMed/NCBI
47	Jiang LH, Mackenzie AB, North RA and Surprenant A: Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors. Mol Pharmacol. 58:82–88. 2000.PubMed/NCBI